2025 brought a revolution in cardiovascular medicine, challenging long-standing practices and sparking debates among experts. But what were the key developments that shaped the year?
Aspirin's Demise?
The year started with a bang as new research questioned the routine use of aspirin, a cornerstone of cardiovascular prevention. The Medical Republic reported on groundbreaking studies revealing that the benefits of aspirin might not outweigh the risks. This led to a re-evaluation of its role in cardiovascular risk protection, with researchers suggesting superior alternatives like clopidogrel. But here's where it gets controversial: one clinical trial had to be stopped due to excess deaths, prompting a rethink of combining aspirin with anticoagulants. This finding has significant implications for clinical practice, as it challenges the traditional approach to stent thrombosis prevention.
Combination Therapies Take Center Stage:
2025 saw a strong push for single-pill combinations (SPCs) or fixed-dose combinations (FDCs) as the first-line treatment for hypertension. Urgent calls for changes to the PBS were made, emphasizing the need for updated guidelines and improved access to these therapies. Despite these calls, as of the time of writing, the PBS restrictions remain in place, and the anticipated updates to the Australian Hypertension Guidelines have yet to be released.
CRISPR's Promise:
Australian researchers made history with the first human trial of CRISPR gene-editing for cholesterol management. This innovative approach showed remarkable results, simultaneously reducing cholesterol and triglycerides. This breakthrough could revolutionize the treatment of mixed lipid disorders, offering a new avenue for patients.
Dyslipidaemia Management Gets an Upgrade:
The European Society of Cardiology and the European Atherosclerosis Society released updated guidelines for dyslipidaemia management, advocating for a more aggressive approach to lipid-lowering. The guidelines highlighted the importance of Lp(a) testing for heart disease prevention, a previously overlooked risk factor. And this is the part most people miss: routine screening could potentially prevent numerous heart attacks, strokes, and early deaths, according to recent research.
PCSK9 Inhibitors in the Spotlight:
The American Heart Association's scientific sessions featured multiple studies on PCSK9 inhibitors, a promising class of cholesterol-lowering drugs. One study found that combining PCSK9 inhibitors with statins provided even greater protection against cardiovascular events, reducing the risk by over 25%.
In a thought-provoking viewpoint, cardiologists from Europe and the US highlighted the impact of these advancements, stating that 2025's clinical trials have reshaped interventional cardiology. They emphasized the improved understanding of antiplatelet management, revascularization timing, and the durability of transcatheter aortic valve implantation (TAVI).
The year 2025 was undoubtedly transformative for cardiovascular medicine, with research and guidelines challenging the status quo. But what does this mean for patients and clinicians? Are we witnessing the dawn of a new era in cardiovascular care, or are these changes merely a blip on the radar? Share your thoughts in the comments below!
